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Abstract: Thoracic aortic aneurysm and dissection (TAAD) is a major cause of cardiovascular mor-
bidity and mortality. Loss-of-function variants in LOX, encoding the extracellular matrix crosslinking
enzyme lysyl oxidase, have been reported to cause familial TAAD. Using a next-generation TAAD
gene panel, we identified five additional probands carrying LOX variants, including two missense
variants affecting highly conserved amino acids in the LOX catalytic domain and three truncating
variants. Connective tissue manifestations are apparent in a substantial fraction of the variant carriers.
Some LOX variant carriers presented with TAAD early in life, while others had normal aortic diam-
eters at an advanced age. Finally, we identified the first patient with spontaneous coronary artery
dissection carrying a LOX variant. In conclusion, our data demonstrate that loss-of-function LOX
variants cause a spectrum of aortic and arterial aneurysmal disease, often combined with connective
tissue findings.
Keywords: TAAD; LOX; ECM; MFS; LDS
1. Introduction
Thoracic aortic aneurysm and dissection (TAAD) is characterized by a progressive
dilatation of the aorta caused by wall weakness that leads to dissection or rupture. Unfor-
tunately, aneurysms often remain unnoticed until dissection or rupture of the aortic wall
occurs. TAAD affects thousands of people every year with a high mortality rate of almost
80%, making it a leading cause of death worldwide. In the Western population alone,
TAAD is responsible for 1–2% of all deaths. More than 30 genes are known to be associated
with TAAD, explaining less than 30% of all familial cases and thus leaving 70% of all
Int. J. Mol. Sci. 2021, 22, 7111. https://doi.org/10.3390/ijms22137111 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 7111 2 of 10
families genetically unexplained [1]. With respect to non-syndromic TAAD, mutations are
typically located in genes that encode for proteins involved in vascular smooth muscle
cell contractility, such as MYH11 and ACTA2. For syndromic TAAD forms, mutations are
found in genes that encode for key players in the transforming growth factor-β (TGF-β)
signaling pathway and extracellular matrix components.
Marfan syndrome (MFS [MIM: 154700]) and Loeys-Dietz syndrome (LDS [MIM:
609192, MIM: 610168, MIM: 613795, MIM: 614816 and MIM: 615582]) are the most ex-
haustively studied TAAD syndromes. MFS is caused by mutations in the FBN1 (fibrillin-1)
[MIM: 134797] gene and is clinically characterized by a pleiotropy of skeletal (e.g., over-
growth), cardiovascular (e.g., TAAD and mitral valve prolapse), ocular (e.g., ectopia lentis)
and skin abnormalities (e.g., striae). LDS is caused by mutations in TGFBR1 [MIM: 190181],
TGFBR2 [MIM: 190182], SMAD2 [MIM: 601366], SMAD3 [MIM: 603109], TGFB2 [MIM:
190220] or TGFB3 [MIM: 190230] and presents with widespread arterial tortuosity and
aneurysms, bifid uvula or cleft palate and hypertelorism [1,2]. The discovery of the in-
volvement of the dysregulation of the TGF-β signaling pathway and the genetic variants
that predispose to heritable aortic disease have led to novel insights [3]. Genes encoding
for proteins that are involved in the assembly of the ECM also predispose to TAAD when
mutated. The aortic wall must be able to withstand a lot of pressure and shear stress and
therefore consists of various structured layers that guarantee the strength and elasticity of
the wall.
Lysyl oxidase, encoded by the LOX gene, is a cuproenzyme that catalyzes crosslinking
of extracellular matrix proteins such as collagen and elastin. The proper assembly of the
latter key structural components of connective tissue matrices is crucial for the stability,
elasticity and mechanical integrity of the aortic/arterial wall. In 2016, two publications [4,5]
reported on the presence of heterozygous loss-of-function variants in the LOX gene in
familial TAAD patients. In 2019, Renner et al. described two additional patients with
LOX variants [6]. At the beginning of 2021, Cirnu et al. identified a missense LOX
variant in a patient displaying arterial aneurysms throughout the body [7]. Using a
next-generation sequencing approach, we aimed to validate the reported contribution
of pathogenic LOX variants to the genetic etiology of TAAD and to further refine the
associated phenotypic spectrum.
2. Results
We report on the identification of heterozygous LOX variants in five novel families,
i.e., two frameshift, one nonsense and two missense variants (Figure 1A,B).
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 2 of 10 
 
 
TAAD is responsible for 1–2% of all deaths. More than 30 genes are known to be associ-
ated with TAAD, explaining less than 30% of all familial cases and thus leaving 70% of all 
families genetically unexplained [1]. With respect to non-syndromic TAAD, mutations are 
typically located in genes that encode for proteins involved in vascular smooth muscle 
cell contractility, such as MYH11 and ACTA2. For syndromic TAAD forms, utations are 
found in genes that encode for key players in the transforming growth factor-β (TGF-β) 
signaling pathway and extracellular matrix components.  
Marfan syndrome (MFS [MIM: 154700]) and Loeys-Dietz syndrome (LDS [MIM: 
609192, MIM: 610168, MIM: 613795, MIM: 614816 and MIM: 615582]) are the most exhaust-
ively studied TAAD syndromes. MFS is caused by mutations in the FBN1 (fibrillin-1) 
[MIM: 134797] gene and is clinically characterized by a pleiotropy of skeletal (e.g., over-
growth), cardiovascular (e.g., TAAD and mitral valve prolapse), ocular (e.g., ectopia len-
tis) and skin abnormalities (e.g., striae). LDS is caused by mutations in TGFBR1 [MIM: 
190181], TGFBR2 [MIM: 190182], SMAD2 [MIM: 601366], SMAD3 [MIM: 603109], TGFB2 
[MIM: 190220] or TGFB3 [MIM: 190230] and presents with widespread arterial tortuosity 
and aneurysms, bifid uvula or cleft palate and hypertelorism [1,2]. The discovery of the 
involvement of the dysregulation of the TGF-β signaling pathway and the genetic variants 
that predispose to heritable aortic disease have led to novel insights [3]. Genes encoding 
for proteins that are involved in the assembly of the ECM also predispose to TAAD when 
mutated. The aortic wall must be able to withstand a lot of pressure and shear stress and 
therefore consists of various structured layers that guarantee the strength and elasticity of 
the wall. 
Lysyl oxidase, encoded by the LOX gene, is a cuproenzyme that catalyzes crosslink-
ing of extracellular matrix proteins such as collagen and elastin. The proper assembly of 
the latter key structural components of connective tissue matrices is crucial for the stabil-
ity, elasticity and mechanical integrity of the aortic/arterial wall. In 2016, two publications 
[4,5] reported on the presence of heterozygous loss-of-function variants in the LOX gene 
in familial TAAD patients. In 2019, Renner et al. described two additional patients with 
LOX variants [6]. At the beginning of 2021, Cirnu et al. identified a missense LOX variant 
in a patient displaying arterial aneurysms throughout the body [7]. Using a next-genera-
tion sequencing approach, we aimed to validate the reported contribution of pathogenic 
LOX variants to the genetic etiology of TAAD and to further refine the associated pheno-
typic spectrum. 
. es lts 
    fi     i ts i  fi  l ili s, 
i. ., t  f i ,         B). 
(A) 
Figure 1. Cont.
Int. J. Mol. Sci. 2021, 22, 7111 3 of 10





Figure 1. (A) Overview LOX protein and location of variants found in five new probands and literature. Variants leading 
to premature stop codons and missense variants are highlighted in, respectively, green and purple [4–7]. (B) Conservation 
of affected LOX amino acids. 
The proband of family 1 (1-III:4; Figure 2) is a 43-year-old male who presented with 
a type A aortic dissection (aorta ascendens diameter: 53 mm) for which he underwent 
aortic root and ascendens replacement. An echocardiography one year prior showed an 
aortic ascendens diameter of 46 mm. His clinical exam did not show specific connective 
tissue findings. The anatomopathological report of the resected aortic tissue showed 
aspecific medial cystic degeneration. The proband was known with arterial hypertension 
and was in follow-up because of a significant family history for aneurysmal disease. Two 
sisters (1-III:1 and 1-III:2) are both being followed because of ascending aortic dilatation 
(44 mm). His brother (1-III:6) had an aortic dissection at age 45 years. The ascending aorta 
diameter at the time of his Bentall surgery was 84 mm. The father (1-II:2) also underwent 
a Bentall surgery at age 60 and died at age 73 due to an acute myocardial infarction. A 
paternal uncle (1-II:3) of the proband died suddenly at age 50 years. No autopsy was per-
formed. The son (1-III:10) of this paternal uncle is married to the sister of the proband (1-
III:9). His MR angio screening at age 43 years showed an aortic sinus diameter of 43 mm 
(Z-score = 2.8; height 172 cm; weight 97 kg) with a sinotubular junction of 38 mm and an 
ascending aorta of 37 mm. Genetic testing of the proband revealed a 14bp deletion in LOX 
(c.53_66delTAGTGCACTGCGCC) leading to a frameshift event and, as a result, the intro-
duction of a premature stop codon (p.(Leu18Profs*111)). Segregation analysis demon-
strated the presence of the LOX variant in the brother (1-III:6), brother-in-law (1-III:10) 
(who is also his nephew) and absence of the LOX variant in an unaffected brother (1-III:8). 
The sister (1-III:2; 56 years) with ascending aorta diameter of 44 mm and chronic hyper-
tension did have a variant of unknown significance (VUS) in FBN1 (c.5810 G > A; 
p.(Gly1937Glu)), but not the LOX mutation. The VUS in FBN1 was also present in patient 
1-III:6. DNA of two other sisters (1-III:1 and 1-III:3) (of which one (1-III:1) also has a dilated 
aorta) is not available. One of the two sons (1-IV:1; 25 years) of the proband also tested 
positive for the familial LOX variant. CT-scan of the entire aorta of this son (1-IV:1) re-
vealed normal aortic diameters. The daughter (1-IV:7) of patient 1-III:10 was also found 
to carry the LOX variant but at age 16 years she still had normal aortic diameters. 
The male proband of family 2 (2-III:1; Figure 2) is currently 40 years old but has a 
history of a type A dissection at age 19 for which he underwent composite graft surgery. 
He has a past medical history of spontaneous splenic rupture, spontaneous pneumotho-
rax and early-onset varicose veins. Genetic testing showed a single nucleotide LOX dele-
tion (c.351delC) leading to a frameshift event and the introduction of a premature stop 
codon (p.(Arg118Glyfs*119)). Familial segregation analysis showed that the LOX variant 
was also present in the father (2-II:1) and in DNA extracted from a colon polyp of the 
paternal grandfather. The paternal grandfather (2-I:1) lived to age 73, had a diagnosis of 
varicose veins, cataract, ischemic heart disease (percutaneous transluminal coronary an-
gioplasty at age 66 years), colon polyps and rheumatoid arthritis. As an infant he was 
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l uncle (1- I:3) of the proban died suddenly t age 50 years. No autopsy was
performed. The son (1-III:10) of this paternal uncle is married to the sister of the proband
(1-III:9). His MR angio scree ing at age 43 year showed an aortic sinus dia t
( - 2.8; height 172 cm; weight 97 kg) with a sinot bular junction of 38 mm and
n asce ding orta of 37 mm. Gen tic testing of the proband revealed a 14 bp deletion
in LOX (c.53_66delT G A TGCGCC) leading to a frameshift event and, as a result,
the introduction of a premature stop codon (p.(Leu18Profs*111)). Segregation analysis
demonstrated the presence of the LOX variant in the brother (1-III:6), brother-in-law (1-
III:10) (who is also his nephew) and absence of the LOX variant in an unaffected brother
(1-III:8). The sister (1-III:2; 56 years) with ascending aorta diameter of 44 mm and chronic
hypertension did have a variant of unknown significance (VUS) in FBN1 (c.5810 G > A;
p.(Gly1937Glu)), but not the LOX mutation. The VUS in FBN1 was also present in patient
1-III:6. DNA of two other sisters (1-III:1 and 1-III:3) (of which one (1-III:1) also has a dilated
aorta) is not available. One of the two sons (1-IV:1; 25 years) of the proband also tested
positive for the familial LOX variant. CT-scan of the entire aorta of this son (1-IV:1) revealed
normal aortic diameters. The daughter (1-IV:7) of patient 1-III:10 was also found to carry
the LOX variant but at age 16 years she still had normal aortic diameters.
The male proband of family 2 (2-III:1; Figure 2) is currently 40 years old but has a
history of a type A dissection at age 19 for which he underwent composite graft surgery.
He has a past medical history of spontaneous splenic rupture, spontaneous pneumothorax
and early-onset varicose veins. Genetic testing showed a single nucleotide LOX deletion
(c.351delC) leading to a frameshift event and the introduction of a premature stop codon
(p.(Arg118Glyfs*119)). Familial segregation analysis showed that the LOX variant was
also present in the father (2-II:1) and in DNA extracted from a colon polyp of the paternal
grandfather. The paternal grandfather (2-I:1) lived to age 73, had a diagnosis of varicose
veins, cataract, ischemic heart disease (percutaneous transluminal coronary angioplasty
at age 66 years), colon polyps and rheumatoid arthritis. As an infant he was operated for
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an incarcerated inguinal hernia. The surgery was complicated by a subsequent infection,
leaving him with a limb. At age of 30 years, he had bilateral hip replacement attributed to
this. At age 50 he suffered from a contralateral inguinal hernia. The father (2-II:1) has a
history of arterial hypertension. His echocardiography (at age 51 years) showed a normal
aortic size and dimension of all four chambers, discrete mitral and aortic valve insufficiency
and no hypertrophy. At age 45 he had an inguinal hernia, mesh repaired with good results.
No other connective tissue complaints. All three affected have suffered from severe eczema.




Figure 2. Pedigrees of LOX families. The probands are indicated with an arrow. Black symbols indicate family members 
that are affected with aortic/arterial aneurysm/dissection. Deceased individuals are indicated with a diagonal line. Plus 
and minus signs are used to indicate the presence and absence of the respective LOX variant. 
The male index patient of family 5 (5-III:1; Figure 2) (21 years) was initially diagnosed 
with aortic dilatation (both at the level of the sinuses and even more pronounced at the 
ascending aorta) at the age of 6. At the age of 14, he underwent elective replacement of 
the ascending aorta because of fast progression (10 mm per 2 years) of its diameter to a 
maximum of 50 mm at the sinotubular junction and above. Microscopic findings showed 
an abnormal texture of the elastic component of the vascular adventitia, with suspicion of 
a connective tissue disorder. His height is at the 95th percentile (Table S1). There is no 
characteristic facial dysmorphism or joint hypermobility and his skin has normal elastic-
ity. His father (5-II:1) committed suicide. Nonetheless, aortic dissection has been reported 
in the father’s family, where the paternal grandfather (5-I:2) and his brother (5-I:1) died of 
acute aortic dissection before the age of 50 years. The mother (5-II:2) was shown to have a 
normal echocardiography. Mutation analysis revealed the presence of a LOX missense 
variant (c.917T > C; p.(Leu306Pro)), which was absent from the unaffected mother. 
According to the ACMG criteria, four out of five LOX variants are predicted to be 
pathogenic (Table S2), whereas variant p.(Leu306Pro) remains a variant of uncertain sig-
nificance. All variants are absent from gnoMAD database. Three variants create prema-
ture stop codons (c.53_66delTAGTGCACTGCGCC; p.(Leu18Profs*111); c.351delC; 
p.(Arg118Glyfs*119) and c.445 G > T; p.(Gly149*)), which are predicted to result in non-
sense-mediated mRNA decay. The LOX missense variants p.(Met298Arg) and 
p.(Leu306Pro) are located in the catalytic domain of LOX (Figure 1A), located at highly 
conserved amino LOX acid positions (Figure 1B) and are predicted to be disease-causing 
by different prediction programs (Table S2). The first one (p.(Met298Arg)) has been pre-
viously reported in a TAAD family and has been proven to affect collagen-elastin cross-
linking and, hence, aortic wall integrity in the respective mouse model [4]. 
Histological staining of aortic wall sections of LOX patients (1-III:4 and 1-III:6) with 
Verhoeff-Van Gieson staining (VVG) revealed increased elastic fiber fragmentation and 
disorganization in comparison to a healthy control (Figure 3). Masson’s Trichrome stain-
ing to assess the collagen content in the same aortic tissue samples showed variable colla-
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that are af ected with aortic/arterial aneurys / . diagonal line. Plus
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e index patient of family 3 (3-II:5; Figure 2) is a 53-years-old m le presenting with a
type A dissection at age 51. He underwent an aortic valve spari g procedure accor ing to
David. He had a normal tricuspid aortic valve, but mild mitral valve regurgitation. He
was negative for cardiovascular risk factors. His physical exam is only significant for tall
stature (191 cm), a narrow palate and pes planus (Table S1). His medical history includes
an inguinal hernia surgery at age 40 and meniscal surgeries due to sport-related injuries.
His father (3-I:1) died of lung cancer at age 73; his mother (3-I:2) lived up to age 81. He has
four siblings (three brothers and one sister). Genetic testing of the index patient revealed a
nonsense variant in LOX (c.445 G > T; p.(Gly149*)). Subsequently, two brothers (3-II:1 and
3-II:4) and a niece (3-III:1) underwent genetic testing, and all three were tested positive for
the familial LOX variant. Cardiac CT-scan of the 56-years-old brother (3-II:4) demonstrated
a borderline aortic sinus measurement of 41 mm (Z-score = 2.3; height: 199 cm; weight:
104 kg), but normal ascending aorta. From his medical history we retain an inguinal
hernia surgery at age 3, a history of hypertension (treated with metoprolol), hypothyroidy
(age 40 years), rupture of the supraspinatus ligament (age 41 years) and tibialis posterior
neuralgia (age 42 years). The other brother (3-II:1; 59 years) also has a history of bilateral
inguinal hernia, tall stature and joint hypermobility. His echocardiographic evaluation
at age 59 years showed no evidence of aortic dilatation. His daughter (3-III:1; 28 years)
underwent “urgent” pre-symptomatic genetic testing because of pregnancy and tested
positive. She is known with joint hypermobility, arachnodactyly, pes planus, shoulder
dislocations and multiple ankle distortions. Her echocardiography revealed normal aortic
dimensions (sinus of Valsalva 28.6 mm; Z-score = 0.28). She is known with hypothyroidy
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(age 19 years), gastric sleeve surgery (25 years), cesarian section (27 years) with premature
delivery (26 weeks) of male newborn who died at one week of age.
This female proband (age 50) of family 4 (4-II:1; Figure 2) has a history of postero-
lateral myocardial infarction due to spontaneous coronary artery dissection at age 44 and a
left internal carotid artery dissection at age 46. She has a history of fibromuscular dysplasia
of the renal arteries, increased skin elasticity, generalized Beighton score of 4/9, enlarged
armspan (167.5 cm; ratio 1.08) and recurrent episodes of ankle dislocation (Table S1).
Wound healing was normal. Echocardiography revealed a diameter of 35 mm at the level
of the sinuses of Valsalva (Z-score = 0.8 for height 154.6 cm and weight 93.9 kg), 26 mm at
the sinotubular junction and 30 mm for the ascending aorta. Genetic testing revealed a LOX
missense variant (c.893T > G; p.(Met298Arg)) which was previously reported as pathogenic
in an unrelated family [4]. Her family history reveals her mother (4-I:2) died at age 58
due to an intracranial bleed of a berry aneurysm but her DNA sample is not available
for testing. The father (4-I:1) and brother (4-II:2) died at, respectively, 58 and 40 years old
due to acute myocardial infarction; both were known with significant cardiovascular risk
factors. Another brother (4-II:3; age 54) is known with chronic obstructive pulmonary
disease (COPD) and no DNA is available from him.
The male index patient of family 5 (5-III:1; Figure 2) (21 years) was initially diagnosed
with aortic dilatation (both at the level of the sinuses and even more pronounced at the
ascending aorta) at the age of 6. At the age of 14, he underwent elective replacement of
the ascending aorta because of fast progression (10 mm per 2 years) of its diameter to a
maximum of 50 mm at the sinotubular junction and above. Microscopic findings showed
an abnormal texture of the elastic component of the vascular adventitia, with suspicion
of a connective tissue disorder. His height is at the 95th percentile (Table S1). There is no
characteristic facial dysmorphism or joint hypermobility and his skin has normal elasticity.
His father (5-II:1) committed suicide. Nonetheless, aortic dissection has been reported in
the father’s family, where the paternal grandfather (5-I:2) and his brother (5-I:1) died of
acute aortic dissection before the age of 50 years. The mother (5-II:2) was shown to have
a normal echocardiography. Mutation analysis revealed the presence of a LOX missense
variant (c.917T > C; p.(Leu306Pro)), which was absent from the unaffected mother.
According to the ACMG criteria, four out of five LOX variants are predicted to
be pathogenic (Table S2), whereas variant p.(Leu306Pro) remains a variant of uncer-
tain significance. All variants are absent from gnoMAD database. Three variants create
premature stop codons (c.53_66delTAGTGCACTGCGCC; p.(Leu18Profs*111); c.351delC;
p.(Arg118Glyfs*119) and c.445 G > T; p.(Gly149*)), which are predicted to result in nonsense-
mediated mRNA decay. The LOX missense variants p.(Met298Arg) and p.(Leu306Pro) are
located in the catalytic domain of LOX (Figure 1A), located at highly conserved amino LOX
acid positions (Figure 1B) and are predicted to be disease-causing by different prediction
programs (Table S2). The first one (p.(Met298Arg)) has been previously reported in a TAAD
family and has been proven to affect collagen-elastin crosslinking and, hence, aortic wall
integrity in the respective mouse model [4].
Histological staining of aortic wall sections of LOX patients (1-III:4 and 1-III:6) with
Verhoeff-Van Gieson staining (VVG) revealed increased elastic fiber fragmentation and
disorganization in comparison to a healthy control (Figure 3). Masson’s Trichrome staining
to assess the collagen content in the same aortic tissue samples showed variable collagen
content in the patients. To investigate the involvement of the TGF-β signaling pathway
in LOX deficiency and TAA development, immunohistochemistry was used to determine
the levels of nuclear pSMAD2 and pERK1/2 in the aortic segments of the LOX patients.
Compared to a control, a larger fraction of pSMAD2 and pERK1/2 positively stained nuclei
can be observed in aortic tissue of both LOX patients (Figure 4).
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3. Discussion
In 2016, (likely) pathogenic variants in LOX were described as a genetic cause for
arterial aneurysm and dissection [4,5]. From the nine initially described variants, three
were premature stop codons (one recurrent p.(Trp42*)) and all six missense variants were
located in the LOX catalytic domain (Figure 1A) [4–7]. We here describe five additional
variants, including three nucleotide deletions or substitutions resulting in a premature stop
codon and two missense variants affecting highly conserved amino acids (Figure 1B) in
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the LOX catalytic domain. Overall, the variant pattern confirms loss-of-function as the
underlying cause.
Comparison of the yet existing literature on TAAD-causing LOX variants with our
own series of patients reveals a number of interesting observations. A summary of the
clinical findings of our cohort of LOX patients and LOX patients in literature can be found
in Table 1. A more detailed overview of the clinical features from literature can be found in
Table S3.
Table 1. Summary of clinical findings of our cohort of patients with LOX variants compared to literature.
Characteristics Literature [4–7] Our Cohort
Total number of patients n = 29 n = 16
Male/female 20/8 (1 unknown) 13/3
Age range at diagnosis 11–73 years (median 46 years) 6–55 years (median 45 years)
Thoracic aortic dissections n = 3 ascending, n = 1 arch n = 4 ascending
Elective surgeries n = 13 (age 11–70 years) n = 1 (age 14 years)
BAV n = 3 n = 0
Disease beyond ascending aorta




Connective tissue findings n = 10 n = 9
First, with regard to the demographic characteristics of the patient population from
literature, there is a wide range in presenting ages from 11 to 73 years (median 46 years)
for cardiovascular findings. In our patient cohort, the earliest aortic aneurysm observation
occurred at age 6 and the first thoracic aortic dissection occurred at age 19. In other families,
we also observed non-penetrance at age 51 years (2-II:1) and 59 years (3-II:1) in family 2
and 3, respectively. As suggested in the prior LOX reports [4,5,7], there is a predilection for
male gender. Overall, 77% (33/44) of the LOX patient population is male. The observation
of male predilection with more severely dilation and more frequent dissection in males has
been observed in other TAAD conditions as well, both in mice and humans [8].
Second, the LOX variants seem to mainly cause aneurysms and dissections at the level
of the thoracic aorta. Overall, eight aortic dissections that have been described, all affecting
the ascending thoracic aorta, except for one that starts in the aortic arch. Thoracic aortic
dissection seems to occur after significant aortic enlargement, with the largest aneurysm
reaching an impressive 125 mm in the ascending aorta. So far, no type B or abdominal
dissections have been described. However, a patient with abdominal aortic aneurysm
has been reported [7]. Arterial disease beyond the ascending aorta seems less frequent,
with an extension of thoracic aortic aneurysm into the brachiocephalic artery, one hepatic
arterial aneurysm and only one patient displaying aneurysm throughout the body in
literature [4,7]. We were the first to report spontaneous coronary artery dissection as part
of the LOX phenotype [9]. We observed no difference between premature stop codon
LOX variants (n = 23) and missense LOX variants (n = 22) with regards to median age of
diagnosis (47.5 years versus 44 years) or severity of the cardiovascular involvement.
Third, extra-aortic cardiovascular features include bicuspid aortic valve disease (3/18
in initial series [5]), as well as mitral and aortic valve insufficiency (n = 3). Arterial tortuosity
has been mentioned once but was still within the normal age-related variation. In our own
patient cohort, we did not observe bicuspid aortic valve disease, whereas mitral and aortic
valve insufficiency were observed once.
Fourth, several patients in the literature (n = 10) and in our series (n = 9) have been
reported to present with other connective tissue findings. These include tall stature (7/19),
pectus deformities (4/19), scoliosis (2/19), joint hypermobility with dislocation (8/19),
inguinal hernia (5/19), skin striae (6/19) and dural ectasia (3/19) [4–7]. As such, there
is significant clinical overlap with other syndromic aortic aneurysmal conditions such
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as Marfan syndrome and Loeys-Dietz syndrome [2]. Remarkably, one of our patients
(proband of family 2) also presented with splenic rupture, a finding also described in
vascular Ehlers-Danlos syndrome and Loeys-Dietz syndrome [2]. We also for the first
time describe the occurrence of spontaneous pneumothorax, a clinical complication well
known to present in several connective tissue disorders [10]. Varicose veins have also
been reported in at least two families (Lee et al., 2016 [4] and family 2 in our cohort). No
connective tissue findings seem specific for LOX mutation carriers, and it also remains
unclear at present why some LOX mutation carriers do not seem to present with connective
tissue findings at all.
Fifth, histopathological findings of the aorta seem rather aspecific, with elastic fiber
fragmentation and cystic medial degeneration. These anatomopathological observations
are a common theme in aortic aneurysmal walls of patients with diverse connective tissue
disorders, but do not allow prediction of the underlying gene defect. Immunohistological
stainings of TGF-β pathway key effectors, pSMAD2 and pERK1/2, revealed an increase
of positively stained nuclei, an indication for increased TGB-β signaling, in aortic tissue
sections from LOX patients. Our observations confirm prior hypothesis that enhanced
TGF-β signaling can contribute to TAA development caused by LOX deficiency [11].
4. Materials and Methods
The cohort consists of genetically undiagnosed patients (n = 16) with aortic or arterial
aneurysm and dissection belonging to 5 families, both in the presence and absence of
connective tissue findings.
Next-generation TAAD gene panel (Table S4) sequencing was performed on DNA
of probands according to previously described methods [12]. In brief, enrichment of the
regions of interest was performed with a custom Haloplex enrichment kit according to
the manufacturer’s protocol (Agilent Technologies). The concentration of each library
was measured by Qubit fluorometric quantification (Life Technologies). For generation of
clusters and subsequent sequencing of the targeted DNA samples on a flow cell, a sequenc-
ing reagent kit from Illumina was used. High-throughput next generation sequencing
data were generated on an Illumina platform. Analysis of the raw data was performed
using Seqpilot (JSI) or a Galaxy pipeline, followed by variant calling with the Genome
Analysis Toolkit (GATK) and variant annotation using an in-house developed tool, Vari-
antDB [13]. Identified variants were genotyped in both affected and unaffected available
family members using Sanger sequencing.
Histological examination was performed on aortic wall tissue from two of our patients
(Family 1 (p.(Leu18Profs*111)), 1-III:4 and 1-III:6) and one control that was collected during
surgery. The collected tissue was embedded in paraffin and sections of 5µm thick were
created. Verhoeff Van Gieson (Sigma-Aldrich) staining was performed to assess elastic fiber
integrity, while Trichrome Masson’s (Sigma-Aldrich) staining was used to evaluate the
collagen content. pSMAD2 and pERK1/2, important components of the TGF-b signaling
pathway, were visualized using immunohistochemistry. Sections were deparaffinized in
toluene for 5 min and rehydrated in alcohol grades of 100%, 90%, 70% and 50%. Sections
were submerged in 3% hydrogen peroxide to inhibit endogenous peroxidase, followed by
10 min in trypsin at 37 ◦C (Sigma-Aldrich, 93615-25G) for antigen retrieval and boiled in
citrate buffer in a microwave for 3 s at 650 W and 10 min at 90 W. Sections were cooled down
at room temperature for 30 min, rinsed with MiliQ and TBST and blocked for 20 min at
room temperature with goat serum (Vector-lab consult). A primary antibody concentration
of 1:5000 and 1:3000 for pSMAD2 (3101, Cell Signaling) and pERK1/2 (4370, Cell Signaling),
respectively, was used to incubate the sections in a humid chamber at room temperature
overnight. The day after, sections were rinsed in TBST followed by incubation with the
secondary antibody (1:200, 30014 Vector, Sec goat anti-rabbit IgG) for 30 min at RT and with
the avidin-biotinylated complex for 1 h at RT (Vectastain ABC kit, Vector Laboratories).
3,3-Diaminobenzidine tetrahydrochloride hydrate (DAB) chromogen (Sigma-Aldrich) was
used as the substrate and Hematoxylin as counterstaining. An automated Nikon Ti-E
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inverted microscope equipped with a Nikon DS-U3 digital camera (Nikon Instruments)
was used to acquire staining images. Nikon NIS Elements AR software v4.51.01 was used
for image acquisition at 10× magnification.
5. Conclusions
Taken together, our data suggest that loss-of-function LOX variants cause a wide
spectrum of aortic and arterial aneurysmal disease, combined with connective tissue
findings such as inguinal hernia, pneumothorax, varices, joint dislocations and splenic
rupture. The time of onset of aortic aneurysm seems variable but can be as early as 6 years
of age. We also report the occurrence of coronary artery dissection as part of the LOX
phenotype.
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